Garon EB, Hellmann MD, Costa EC, et al. Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. ASCO Annual Meeting 2019, abstract LBA9015.
TMB in bloed als biomarker voor effectiviteit immuuntherapie bij NSCLC
apr 2019 | Immuuntherapie, Longoncologie